AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06684769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emdogain® FL
Description: Enamel Matrix Derivatives
Study NCT06684769 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Labrida BioClean®
Description: Oscillating Chitosan Brush
Study NCT05975359 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interi Manifold Drain System
Description: The Interi manifold surgical drain system will be placed in the breast pocket during stage 1 immediate implant based breast reconstruction. Output of the interi drain will be monitored daily and the Interi drain will remain in the surgical site until criteria for drain removal are met. Removal of the Interi drain will be performed in clinic by surgical staff.
Study NCT05975359 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jackson Pratt Drain System
Description: The Jackson Pratt surgical drain system will be placed in the breast pocket during stage 1 immediate implant based breast reconstruction. Output of the Jackson Pratt drain will be monitored daily and the drain will remain in the surgical site until criteria for drain removal are met. Removal of the Jackson Pratt drain will be performed in clinic by surgical staff.
Study NCT06373068 — intervention group
Intervention type: OTHER
Intervention: Resuscitation orders
Description: Resuscitation orders, commonly referred to as Code Status, communicate to the healthcare team the specific medical interventions that patients will receive while hospitalised. These orders are issued by a doctor and require confirmation by at least one other licensed medical professional
Study NCT06684769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Labrida BioClean®
Description: Oscillating Chitosan Brush
Study NCT05919030 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Description: Esophageal primary tumor: 39.6Gy/2.2Gy Bone metastasis: 30Gy/3Gy Lung, liver, brain metastases, metastatic lymph nodes: 45Gy/3Gy
Study NCT05919030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg IV Q3W
Study NCT05919030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tislelizumab
Description: 200 mg IV Q3W
Study NCT05919030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: During concurrent radiation therapy: 25 mg/m² IV QW During consolidation therapy: 75 mg/m² IV Q3W
Study NCT05919030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: During concurrent radiation therapy: 25 mg/m² IV QW During consolidation therapy: 75 mg/m² IV Q3W
Study NCT05919030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: During concurrent radiation therapy: 75 mg/m² IV QW During consolidation therapy: 220 mg/m² IV Q3W
Study NCT05919030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab paclitaxel
Description: During concurrent radiation therapy: 75 mg/m² IV QW During consolidation therapy: 220 mg/m² IV Q3W
Study NCT04013971 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: AGRF Biofeedback Game
Description: During the AGRF biofeedback game participants will walk on a split-belt treadmill with a projector or screen display. Participants will be receiving real-time information or feedback about ongoing gait performance parameters while they are walking. The participants will be exposed to the AGRF biofeedback game for 4 minutes.
Study NCT04013971 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Traditional Biofeedback Interface
Description: For the traditional non-game biofeedback, the visual display comprises a horizontal line graph with a moveable cursor that represents the current measured value of antero-posterior ground reaction force for the targeted leg. The auditory feedback comprises an audible beep produced every time the cursor entered the target range. Participants will be exposed to the traditional biofeedback interface for 4 minutes.
Study NCT04013971 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Condition
Description: Participants will complete a control walk with out feedback.
Study NCT06418906 — intervention group
Intervention type: OTHER
Intervention: Self-reported questionnaires
Description: After participants agree to participate in this study, they will first fill out the set of questionnaires once. After two weeks, the research team will send them reminders to fill out the same set of questionnaires again.
Study NCT04013971 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Optional Game with VR
Description: During the optional AGRF biofeedback game with virtual reality (VR) participants will walk on a split-belt treadmill with a head-mounted VR display. Participants will be receiving real-time information or feedback about ongoing gait performance parameters while they are walking. The participants will be exposed to the AGRF biofeedback game with VR for 4 minutes.
Study NCT05803772 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: APHD-012
Description: Drug: APHD-012 Distal jejunal-release dextrose beads (Aphaia technology, AT)
Study NCT05803772 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: APH-012P
Description: Distal jejunal-release placebo beads
Study NCT03708809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrauterine system
Description: 13.5 mg levonorgestrel-releasing intrauterine system
Study NCT03708809 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Alternative contraception to intrauterine system
Description: Alternative contraception including contraception pills, hormonal patches, hormonal vaginal , condomsring,
Study NCT05284071 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: Actiste 1.0 and the Companion app with TBL Backend
Description: Actiste automatically logs and shares real-life data on blood glucose values and actual injected insulin doses. With Actiste's built-in sensor, the exact injected dose is displayed and saved in the device memory together with a time stamp, which makes it easy for the user to know how much and when the insulin was injected, and spot missed doses. This simplifies the daily diabetes care for the user and thus may improve the quality of life for people with diabetes and may improve the patients' adherence to treatment plans. Actiste automatically logs and shares real-life data on blood glucose values and actual injected insulin doses. With Actiste's built-in sensor, the exact injected dose is displayed and saved in the device memory together with a time stamp, which makes it easy for the user to know how much and when the insulin was injected, and spot missed doses. This simplifies the daily diabetes care for the user and thus may improve the quality of life for people with diabetes.
Study NCT05686980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-552
Description: Oral Capsule
Study NCT04920682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reversal of moderate neuromuscular blockade
Description: Neostigmine 60 mcg/kg when TOF (Train-of-Four) = 3 and saline when TOF (T4 / T1)> 0.4
Study NCT04920682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reversal of superficial neuromuscular blockade
Description: Neostigmine 30 mcg/kg when TOF (T4 / T1)> 0.4
Study NCT06570356 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Geriatric Depression Scale - 15
Description: a validated screening tool designed to identify depression in older adults. It consists of 15 simple yes/no questions that assess depressive symptoms.
Study NCT05185453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strengthening Connections for Change
Description: Strengthening Connections for Change is a 12-session curriculum designed to strengthen adolescent-adult support networks, build leadership skills, foster community engagement, and challenge attitudes and behaviors that foster violence involvement. During the program, youth ages 13-17 years invite their self-identified key adult supports to jointly participate in programming including youth-focused, adult-focused and jointly focused activities. Towards the end of programming participants design and carry out a community project to strengthen intergenerational connections and promote community engagement.
Study NCT04920682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Two-step reversal
Description: Neostigmine 30 mcg/kg when TOF = 3 and neostigmine 30 mcg/kg when TOF (T4 / T1)> 0.4
Study NCT04920682 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline solution (SF) when TOF = 3 and when TOF (T4 / T1)> 0.4
Study NCT04894292 — intervention group
Intervention type: OTHER
Intervention: Non intervention
Description: During the study there is no extra intervention planned for the participants.
Study NCT06002243 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SPLASH echocardiography screening
Description: Screening echocardiogram performed by a briefly trained health worker with images reviewed off site by an expert cardiologist or cardiac sonographer to determine screening outcome. Screening outcome may include: screen positive, screen negative or uninterpretable images.
Study NCT05185453 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Job Readiness Training
Description: Job Readiness Training uses a group discussion format to learn specific skills to prepare for employment including developing goals, seeking jobs, preparing for interviews, and so forth.
Study NCT06471673 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BC1 cell line
Description: BC1 cell line is a different experimental, HER-2 positive, allogeneic, whole cell BC cell lines designed to secrete GM-CSF in situ and augment dendritic cell activity. Similar to the SV-BR-1-GM cell line (NCT03328026, IND 10312), the BC cell line is derived from the BC parent cell line, SV-BR-1, which expresses multiple tumor associated antigens (TAAs)
Study NCT06471673 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bria-OTS regimen and CPI (tislelizumab)
Description: Biological: BC1~* BC1 inoculation intradermally at 4 sites~Drug: Low dose cyclophosphamide~* Pretreatment with low dose cyclophosphamide 2-3 days prior to BC1 inoculation~Drug: Interferon~* Subjects will receive low dose peginterferon alpha-2a on the same day as cell inoculation.~Drug: Tislelizumab~* CPI treatment will also be given on the same day as cell inoculation.
Study NCT06471673 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bria-OTS regimen and CPI (tislelizumab) expansion cohort
Description: Biological: BC1~* BC1 inoculation intradermally at 4 sites~Drug: Low dose cyclophosphamide~* Pretreatment with low dose cyclophosphamide 2-3 days prior to BC1 inoculation~Drug: Interferon~* Subjects will receive low dose peginterferon alpha-2a on the same day as cell inoculation.~Drug: Tislelizumab~* CPI treatment will also be given on the same day as cell inoculation.
Study NCT06222606 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery with autofluorescence
Description: In the experimental group, the surgeon will use the EleVision IR camera system (Medtronic, USA) to visualize parathyroid glands during surgery.
Study NCT06692465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT20029 Tincture
Description: 5mg (0.5%) and 10mg (1%) one single dose per day (QD) treatment over 12 weeks period; 5mg (0.5%) and 10mg (1%) twice per week (BIW) treatment, on every Monday and Thursday over 12 weeks period
Study NCT05721469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art therapy
Description: Determining the mothers of children with eating disorders with the data obtained from the questionnaires and scales and separating them into randomized experimental and control groups, 8-12 sessions of 90 minutes of music, painting, ceramics, etc. were given to the mothers participating in the experimental group. Art Therapy Studies
Study NCT06492551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trak exercise prescription protocol
Description: Online treatment based on therapeutic exercise using the Trak software. The patient will undergo 6 weeks of an exercise prescription protocol based on strength, balance, proprioception, and aerobic exercises. Physical therapy techniques to improve secretion management and respiratory mechanics will also be included.
Study NCT06692465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GT20029 matching placebo
Description: 5mg (0.5%) and 10mg (1%) matching placebo one single dose per day (QD) treatment over 12 weeks period; 5mg (0.5%) and 10mg (1%) matching placebo twice per week (BIW) treatment, on every Monday and Thursday over 12 weeks period
Study NCT06693700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indoor Air Quality Monitor AirGradient ONE
Description: Participants will be asked to set up an Indoor Air Quality Monitor AirGradient ONE (Model: I-9PSL) which is an award winning commercially available indoor air quality monitor designed to enable anyone to monitor their air quality in their home for about 60 days (8 weeks). Indoor air pollution levels within participating households will be measured using these AQMs.
Study NCT06492551 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation plan in the gym
Description: Treatment is based on therapeutic exercise following a conventional rehabilitation plan. The patient will undergo 6 weeks of an exercise prescription protocol based on strength, balance, proprioception, and aerobic exercises. Physical therapy techniques will also be included to improve secretion management and respiratory mechanics.
Study NCT06321055 — intervention group
Intervention type: DRUG
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Retrospective analysis.
Study NCT05768178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Participants will receive vemurafenib at a dose of 960 mg orally on a twice daily schedule throughout a 28-day cycle.
Study NCT05768178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Participants will receive cobimetinib at a dose of 60 mg (3 tablets of 20 mg) to be taken orally, once daily for 21 consecutive days (days 1 to 21 in each 28-day cycle); followed by a 7-day break.
Study NCT06604195 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified sciatic nerve mobility exercises
Description: Each participant was made to lie down in a supine position on the treatment couch. The participant's leg was moved to about 30-45 degrees hip flexion with knee extension. The ankle was then moved to maximum dorsiflexion with inversion and hip internal rotation within the participant's tolerance, and this position was maintained for 30 seconds. While the therapist performed dorsiflexion with inversion and hip internal rotation in the supported straight leg raise position, the participant was instructed to actively flex the cervical spine slowly until they perceived a tolerable stretch sensation in the hamstring muscle and lower leg. The synchronous alternating movements were performed rhythmically for 10-15 repetitions. This maneuver was repeated 3 times in a single session, 3 days per week, and continued for 3 consecutive weeks.
Study NCT06604195 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic hamstring muscle stretching
Description: The participant was instructed to stand straight with the unaffected foot supported on the floor and the toes pointing forward. The heel of the testing leg was placed on an 18 high step with the toes directed upwards with knee extension. Once cued, the participant was asked to flex forward at the hip while maintaining the spine in a neutral position and reaching the arms forward. The knee joint remained fully extended as the participant continued to flex the hip until a gentle stretch was felt in the posterior thigh. Once the position was achieved, the participants were asked to hold it for 20-30 seconds. The same procedure was repeated 3 times daily, 3 days a week for three consecutive weeks.
Study NCT06678282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JY231 Injection
Description: The starting dose of this study was set at 1\~10×10\^6 transduction units (TU) / kg and escalated at 2\~5×107\^TU/kg and 6\~10×10\^7 TU/kg.
Study NCT06678217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stroop task
Description: The Stroop task will be used as a mild, acute stressor since it has effects on anxiety and autonomic response. In each Stroop task condition, four coloured visual stimuli will be presented on a computer screen for 3 s with 7 s inter-stimulus interval. The stimuli will be coloured words naming the colour of the ink in the nonconflict task condition (e.g. GREEN written in green ink) and a different colour in the conflict task condition (e.g. GREEN written in red ink). The participants were asked to name the colour of the stimuli. The test will be administered using the online version of PsyToolKit (Stoet, 2021).
Study NCT06678217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold pressor test
Description: The participant lowers their hand in icy water to induce temporary tonic pain
Study NCT06678672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Description: The participants will receive and be trained to use a CO monitor and iCO app to upload videos to verify smoking abstinence at a minimum of once per day, 5 times per week, over 5 weeks. Financial incentives will be provided at weekly visits contingent on tobacco abstinence verified through remote CO monitoring. They will receive clinician feedback at the time of each CO reading, following the established VA CM protocol developed in the earlier phase of the project. Each CO reading during the weeks 2-5 will also be accompanied with a brief (5-minute) telephone or video feedback CM counseling session from the study clinician.
Study NCT06678672 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Participants assigned to TAU will receive usual care at San Francisco VA Health Care System (SFVAHCS), i.e., referral to Tobacco Cessation Clinic and the VA Telequit Quitline. The SFVAHCS Tobacco Cessation Clinic is a consult service that calls patients proactively 3 times to offer 1:1 behavioral counseling for smoking cessation. VA Telequit is a national toll-free number available to Veterans that allows them to speak with a smoking cessation counselor for up to 5 sessions per NCI Quitline guidelines. The smoker initiates the first call, and subsequent calls will be proactively made by Quitline staff.
Study NCT06679556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Strength A Sublingual Minoxidil
Description: One single dose of Strength A sublingual minoxidil
Study NCT06679556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Strength B Sublingual Minoxidil
Description: One single dose of Strength B sublingual minoxidil
Study NCT06677736 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional scaling and debridement
Description: conventional scaling and debridement
Study NCT06677736 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Diode laser as adjunctive to conventional scaling and debridement
Description: Diode laser as adjunctive to conventional scaling and debridement
Study NCT06679673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701
Description: SHR-1701
Study NCT06679673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP102
Description: BP102
Study NCT06679673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2554
Description: SHR2554
Study NCT06677944 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative PBI
Description: Preoperative PBI: 21 Gy \* 1 fraction Preoperative PBI is administered within 6 weeks of the patient's initial registration, and surgery is scheduled within 8 to 12 weeks after PBI.
Study NCT05039489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antipsychotic drugs
Description: Stable antipsychotic medication 4 weeks before and during the treatment. Chlorpromazine (CPZ) equivalent dosages were calculated for second- and first-generation antipsychotic drugs
Study NCT05039489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antipsychotic drugs
Description: Stable antipsychotic medication 4 weeks before and during the treatment. Chlorpromazine (CPZ) equivalent dosages were calculated for second- and first-generation antipsychotic drugs
Study NCT05039489 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cTBS（the left temporoparietal cortex as the stimulation target）
Description: Participants received 3 daily sessions of cTBS treatment. One session of cTBS was 40 seconds in duration and consisted of 3-pulse bursts at 50 Hz repeated every 200 milliseconds (5 Hz) until a total of 600 pulses was reached. To achieve cumulative aftereffects, this protocol was repeated 3 times and (1800 pulses in total) separated by two 15 minute breaks
Study NCT05039489 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cTBS （the left cerebellum Crus II as the stimulation target）
Description: Participants received 3 daily sessions of cTBS treatment. One session of cTBS was 40 seconds in duration and consisted of 3-pulse bursts at 50 Hz repeated every 200 milliseconds (5 Hz) until a total of 600 pulses was reached. To achieve cumulative aftereffects, this protocol was repeated 3 times and (1800 pulses in total) separated by two 15 minute breaks
Study NCT05484778 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dual tasking paradigm
Description: The dual task methodology is a testing model that requires one person to perform two tasks at the same time. The dual task is divided into two as motor-motor or motor-cognitive. Dual tasks provide an opportunity to examine the attention demands of both tasks and allow possible interference to be observed. The idea behind this design is that central processing capacity has a limit and must be distributed among concurrent tasks.
Study NCT05034133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab (IV 1000mg on day 1) with chemotherapy (Etoposide and Cisplatin) for 6 cycles